OncoGenex Pharmaceuticals has announced the commencement of a fourth Phase II genitourinary (GU) cancer study, as part of its OGX-427 Overcoming Resistance in Cancer (ORCA) programme.
The Borealis-2 investigator-sponsored trial is a randomised, controlled Phase II study designed to assess OGX-427 in patients with advanced or metastatic bladder cancer, in whom disease has progressed after the initial platinum-based chemotherapy treatment.
Memorial Sloan-Kettering Cancer Center associate physician Jonathan Rosenberg said that when bladder cancer patients relapse, resistance to chemotherapy is common.
"This trial will evaluate the potential of OGX-427 to work synergistically with second- or third-line chemotherapy to overcome treatment resistance and prolong survival in patients with advanced bladder cancer," Rosenberg said.
The study will assess if OGX-427 and docetaxel combination therapy can improve survival compared to docetaxel alone.
OncoGenex president and chief executive officer Scott Cormack said; "The launch of Borealis-2 marks OncoGenex’ continued commitment to expanding the OGX-427 clinical development programme to better understand treatment resistance in GU cancers."
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOGX-427 is designed to restrain Heat Shock Protein 27 (HSP27), the over expression of which is believed to be a crucial factor for the development of treatment resistance, in addition to producing negative clinical outcomes in patients with various tumour types.
HSP27 is a cell-survival protein found at elevated levels in many human cancers such as prostate, bladder, breast and non-small cell lung cancer.